featured
Neoadjuvant Nivolumab With or Without Relatlimab for Resectable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Nat. Med. 2024 Apr 30;[EPub Ahead of Print], M Schuler, K Cuppens, T Plönes, M Wiesweg, B Du Pont, B Hegedus, J Köster, F Mairinger, K Darwiche, A Paschen, B Maes, M Vanbockrijck, D Lähnemann, F Zhao, H Hautzel, D Theegarten, K Hartemink, H Reis, P Baas, A Schramm, C AignerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.